Literature DB >> 26984850

Visceral Leishmaniasis May Unmask X-linked Hyper-IgM Syndrome.

Luis Ignacio Gonzalez-Granado1,2, Nerea Dominguez-Pinilla3,4, Fernando Gallego-Bustos5, Jesús Ruiz-Contreras3,4, Luis M Allende5,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26984850     DOI： 10.1007/s10875-016-0270-9

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  9 in total

Review 1.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

2.  CD40 ligand is required for protective cell-mediated immunity to Leishmania major.

Authors:  K A Campbell; P J Ovendale; M K Kennedy; W C Fanslow; S G Reed; C R Maliszewski
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

Review 3.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

4.  CD40-CD40 ligand costimulation is not required for initiation and maintenance of a Th1-type response to Leishmania major infection.

Authors:  Udaikumar M Padigel; Jay P Farrell
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

5.  The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients.

Authors:  Jerry A Winkelstein; Mary C Marino; Hans Ochs; Ramsey Fuleihan; Paul R Scholl; Raif Geha; E Richard Stiehm; Mary Ellen Conley
Journal:  Medicine (Baltimore)       Date:  2003-11       Impact factor: 1.889

6.  Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome.

Authors:  Wen-I Lee; Troy R Torgerson; Michael J Schumacher; Leman Yel; Qili Zhu; Hans D Ochs
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

Review 7.  CD40 and the immune response to parasitic infections.

Authors:  Carlos S Subauste
Journal:  Semin Immunol       Date:  2009-07-18       Impact factor: 11.130

8.  Soluble CD40 Ligand in Sera of Subjects Exposed to Leishmania infantum Infection Reduces the Parasite Load in Macrophages.

Authors:  Fabrícia Alvisi de Oliveira; Aline Silva Barreto; Lays G S Bomfim; Talita Rebeca S Leite; Priscila Lima Dos Santos; Roque Pacheco de Almeida; Ângela Maria da Silva; Malcolm S Duthie; Steven G Reed; Tatiana Rodrigues de Moura; Amélia Ribeiro de Jesus
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

9.  Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency.

Authors:  Waleed Al-Herz; Aziz Bousfiha; Jean-Laurent Casanova; Talal Chatila; Mary Ellen Conley; Charlotte Cunningham-Rundles; Amos Etzioni; Jose Luis Franco; H Bobby Gaspar; Steven M Holland; Christoph Klein; Shigeaki Nonoyama; Hans D Ochs; Erik Oksenhendler; Capucine Picard; Jennifer M Puck; Kate Sullivan; Mimi L K Tang
Journal:  Front Immunol       Date:  2014-04-22       Impact factor: 7.561
  9 in total
  2 in total

1.  Variants Disrupting CD40L Transmembrane Domain and Atypical X-Linked Hyper-IgM Syndrome: A Case Report With Leishmaniasis and Review of the Literature.

Authors:  Boaz Palterer; Lorenzo Salvati; Manuela Capone; Valentina Mecheri; Laura Maggi; Alessio Mazzoni; Lorenzo Cosmi; Nila Volpi; Lucia Tiberi; Aldesia Provenzano; Sabrina Giglio; Paola Parronchi; Giandomenico Maggiore; Oreste Gallo; Alessandro Bartoloni; Francesco Annunziato; Lorenzo Zammarchi; Francesco Liotta
Journal:  Front Immunol       Date:  2022-04-28       Impact factor: 8.786

2.  Case Report: Hyper IgM Syndrome Identified by Whole Genome Sequencing in a Young Syrian Man Presenting With Atypical, Severe and Recurrent Mucosal Leishmaniasis.

Authors:  Camilla Heldbjerg Drabe; Rasmus L Marvig; Line Borgwardt; Jens D Lundgren; Hanne Vibeke Hansen Maquart; Terese Lea Katzenstein; Marie Helleberg
Journal:  Front Immunol       Date:  2020-09-11       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.